الفهرس 
Chronic liver diseaseOnly 14 pages are availabe for public view
 |  | from | 180 |  |  |
| | | from | 180 | | |
Abstract
(88)
SUMMARY AND CONCLUSION
This work aimed to find a relation between the level of
to
ICAM-I and upper respiratory tract infections which procee complications as a prelimin step for the use of solubd
le
mmon colds w
ICAM-1 as a protective treatmenary t for co
causative viruses are rapidly changing. hose
This study was carried out on 30 patients complaining of upper respiratory tract infections and/or its complications eal .g• otitis s
investigations media. The patient were subjected to bacteriologi-c which they were classified as ira-tory tract infection due to bacterial agent (group I) upper andresp upper respiratory tract infection due to a non bacterial agenti, e. vi-ral, fungal (group II).
The study showed that there was
ence in almost all the no significant differ-
parame ymphocytes count (absoluted level of IC ters done, i.e., white cell count, haemoglobin concentration, l
relative), granulocytic count (absolute and relative ) and also AM-I in serum between the two
between the groups and the reference group. grou ps and in-
This study proved that there is no
bacterial and non-bacterial u difference between
pper respiratory tract infections as regards the concentration of the circulating solu AM-1, which has probably been bound to their receptors.ble This
carry the hope of the assumption f night
for the preparation of a synthetic soluble ICAM-I analog which might be used to from
block the receptors of ICAM-1 and prevent the symptoms P
to complication. This more
work on a wider scale to verify or dispute need
it.